NITRO is a two stage, single centre, phase II, single arm study using neo-adjuvant, intravitreal ranibizumab treatment in high risk ocular melanoma patients.
Ranibizumab will be administered via the eye on the first day of treatment. If after 28 days the tumour has reduced, but not enough for eye preservation treatment, the Ranibizumab treatment will be repeated. Ranibizumab will be given up to a maximum of six times, every 28 days. Should the tumour increase, patients will revert to standard eye removal treatment.
The study will recruit 25 patients from The Royal Liverpool Hospital, referred in from anywhere within the country.
If the neo-adjuvant treatment is sucessful in reducing tumour size, it may lead to future eye and sight preserving treatments as oppossed to immediate eye removal.
Sorry there are currently no job vacancies
"The experience and treatment I received at the Royal Liverpool Hospital was so fantastic that I had to tell the people involved with my treatment how marvelous they were, so please would you pass on my thanks and gratitude to Professor Neoptolemos and his team of surgeons, the wonderful doctors and nursing staff" - Anon (Participant in ESPAC-3(v2) trial)
Read more Patient stories